anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A mobile information terminal (109) stores, in a time sequence, measurement information transferred from sensors into a data memory (110). A CPU of the mobile information terminal (109) analyzes the measurement results by use of an analysis program (111) to determine whether any of the measurement results indicates any extraordinary value. If the output result of the analysis program (111) indicates any response that is different from a normal one, then the mobile information terminal activates a diagnosis-by-asking-questions program. The CPU uses the diagnosis-by-asking-questions program (112) to ask questions so as to determine whether the extraordinary biometric information extracted from the sensors is caused by any deficiencies such as fault conditions or omissions of the sensors, or by a variation in the psychological condition of the user, or by a variation in the physical condition of the user. Answers to the questions are entered by the user (101) itself into the mobile information terminal (109). This is used for home-based medical care and telemedicine or directed to support such a diagnosis of disease or such a health maintenance that is difficult for any medical institutions to provide.
Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein.  The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.
3q29 deletion syndrome (3q29del) is associated with neuropsychiatric and neurodevelopmental phenotypes. We previously reported that graphomotor weakness is present in up to 78% of individuals with 3q29del. We have now explored nuances of the graphomotor phenotype and its association with other comorbidities in this population. Participants were recruited from the online 3q29 registry (3q29deletion.org) for two days of deep phenotyping. 32 individuals with 3q29del (62.5% male) were evaluated with the Beery-Buktenica Developmental Test of Visual-Motor Integration (VMI) to assess visual-motor integration. Participants were also evaluated with measures of cognitive ability, executive function, adaptive behavior, and school function. Males with 3q29del performed significantly worse than females on the VMI and Motor Coordination subtest. VMI performance was significantly associated with ADHD diagnosis and cognitive ability. Compared to published data from individuals with 22q11.2 deletion syndrome, individuals with 3q29del showed significantly more impairment. The 3q29 deletion is associated with substantial deficits in visual-motor integration, Visual Perception, and Motor Coordination. Our data suggests that 3q29del may qualify as a nonverbal learning disability. Future studies should assess whether individuals with 3q29del would benefit from early interventions, including occupational therapy.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to the pharmaceutical industry, and more particularly to an agent for the prevention or treatment of a malignant tumor such as lung cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, breast cancer or ovarian cancer. Disclosed is a combination for the prevention or treatment of a cancer that comprises metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof, wherein the malignant tumor is lung cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, breast cancer or ovarian cancer, and the content of metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof in combination is 1–600 moles of metforminor a pharmaceutically acceptable salt thereof per 1 mole of dihydroquercetin or a pharmaceutically acceptable salt thereof. Use of dihydroquercetin or a pharmaceutically acceptable salt thereof in combination with metformin or a pharmaceutically acceptable salt thereof for the preparation of the combination. Method for preventing or treating a malignant tumor, comprising administering a combination to an individual in need thereof. Drug for the prevention or treatment of pancreatic cancer. Method for the prevention or treatment of pancreatic cancer. Use of dihydroquercetin or a pharmaceutically acceptable salt thereof as a medication for the prevention or treatment of pancreatic cancer as a combination thereof. Use of dihydroquercetin or a pharmaceutically acceptable salt thereof for the preparation of a medication for the prevention or treatment of pancreatic cancer. Medication for the prevention or treatment of a malignant tumor comprising metformin or a pharmaceutically acceptable salt thereof for use in combination. Medication for the prevention or treatment of a malignant tumor, comprising dihydroquercetin or a pharmaceutically acceptable salt thereof for use in combination.EFFECT: above described agents have unexpected therapeutic activity in the prevention or treatment of a malignant tumor such as lung cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, breast cancer or ovarian cancer.14 cl, 7 dwg, 8 tbl, 12 ex
Hepatocellular carcinoma remains a significant worldwide malignancy and an important cause of cancer-related death. The incidence is increasing globally. In Latin America, there is no consistent data on the epidemiology of hepatocellular carcinoma. However, Brazil is considered a country with an intermediate incidence of this liver neoplasm. In the state of Ceará, situated in the northeast region of Brazil, there are no consistent clinical and epidemiologic data on the actual incidence and the treatment of hepatocellular carcinoma. The purpose of this article is to describe epidemiologic characteristics and treatment forms of patients with hepatocellular carcinoma who were treated in a Liver Transplant Center. A retrospective observational study was conducted using the database from the register of 299 patients with hepatocellular carcinoma between June 2004 and February 2022. Only patients born in Ceará were included. Therefore, most patients were eligible, based on the Milan Criteria, to undergo liver transplantation with a Model End Stage Liver Disease score of 12.48 ± 4.66 points, and the waiting list time was approximately 7 months with 8.7% hepatocellular carcinoma recurrence after liver transplant. A total of 38.5 % of cases were outside the Milan criteria at the time of cancer diagnosis, and transarterial chemoembolization was the main treatment choice. In conclusion, the diagnosis of hepatocellular carcinoma in Ceará mainly occurs in male patients with hepatitis C or alcoholism, with a mean age of 61.55 years and a previous diagnosis of liver disease. Liver transplantation was the best curative therapeutic form in patients with cirrhosis and hepatocellular carcinoma in Ceará, where a significant number of patients were diagnosed with intermediate and advanced-stage hepatocellular carcinoma, so public health policies are important for the screening and monitoring of liver disease.
Participants randomized to this arm will receive personalized diet, activity, and weight loss goals as well as tools to self-monitor behaviors and weight. To facilitate changes, participants will receive coaching calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
It is intended to provide a novel compound having an excellent PDE4 inhibitory activity and TNF-.alpha. production-suppressing activity. It is also intended to provide a preventive and therapeutic agent for atopic dermatitis or the like. The invention comprises a novel phthalazinone derivative represented by the following general structural formula [1], a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient. [Chemical formula 12] [1] In the structural formula [1], the following partial structure between positions 6 and 7 represents a single bond or a double bond. [Chemical formula 13] R1 and R2 represent alkyl or the like, Y represents phenylene or the like, Z represents alkylene or the like, R3 represents a mono- to tri-cyclic saturated or unsaturated cyclic amino group or the like and R31 and R32 represent alkyl or the like.
The primary aim is to evaluate the feasibility of comprehensive ABCDEFG-SE in the evaluation of HCM. The secondary aim is to assess the value of each of obtaained parameters in predicting response to specific therapy and other interventions. The tertiary aim is to assess the prognostic value of SE indices for prognostic stratification in the medium-long-term. HCM diagnosis will be based on existing guidelines. All patients will be followed-up. In patients and first-degree relatives with genetic characterization different phenotypes will be correlated with specific genotypes. Non-imaging or routine imaging non-ultrasound exams will be collected and analyzed with neural network analysis developed in project 5. We assume that a sample size of 338 patients is required.
The present invention relates to a safflower yellow orally disintegrating tablet and a preparation process thereof. The safflower yellow orally disintegrating tablet has the effects of coronary arteriae dilation, antioxidation, myocardium protection, blood pressure decrease, immunodepression and brain protection, etc. The present invention aims at making up for the preparation insufficiency of existing safflower yellow preparation and providing a safflower yellow orally disintegrating tablet and a preparation process thereof for all patients and medical workers; the safflower yellow orally disintegrating tablet has the advantages of convenient use and rapid absorption and effect-taking. Safflower yellow is used as raw material; filling agents, disintegrating agents, corrigents, flow aid, lubricating agents, etc. are used as auxiliary materials; adhesives or coating materials can also be used according to different situations; appropriate quantity of effervescent agents can be added on specific situation; the orally disintegrating tablet is prepared by a specific preparation method and obtained after tabletting by tabletting machines. The orally disintegrating tablet of the present invention has the characteristics of good friability, rapid disintegration, good taste, no gravel feel, no need of specific production condition, low production cost, convenient carry, storage, transportation and use, etc.; most of all, the orally disintegrating tablet can be taken without water and takes effect quickly, and therefore, the present invention improves the patient's compliance and enhances the curative effect of the medicine.
This proposal describes a combined observational study (Phase I) and randomized controlled trial (Phase II). The primary aim of the observational study is to determine the disorders, in particular the types of depression, for which family physicians prescribe antidepressants. The primary aim of the randomized controlled trial (RCT) is to compare the effect of a brief psycho-educational intervention by pharmacists with usual care on antidepressant persistence.

Subjects (n=621 phase 1, n=106 phase 2) will be patients presenting to a pharmacy in Edmonton with a prescription for an antidepressant from a family physician and meeting the following criteria: no antidepressants taken in the preceding six months; 18 years of age or older, and fluent in English. Subjects will be interviewed using modified versions of the depression, generalized anxiety disorder and panic disorder sections of the Diagnostic Interview Schedule; the Beck Depression Inventory; the Beck Anxiety Inventory; and a question on recent stressful life events. For Phase 1 the proportion of subjects with the following DSM-IV diagnoses will be estimated: major depression, "minor depression," generalized anxiety disorder, panic disorder; minor depression will be categorized into "adjustment disorder with depressed mood" and "adjustment disorder with mixed anxiety and depressed mood". The family doctor will be contacted and asked for the diagnosis that prompted the antidepressant prescription.

Subjects with DSM IV depression will be invited to participate in Phase 2. Individuals will be randomized to a pharmacist intervention with the Health PACT, or to usual care. Using the newly-developed Antidepressant Compliance Questionnaire, information on predictors of adherence will be collected at the baseline interview. At weeks 4, 8, 16 and 26, subjects will be contacted by phone and questioned on antidepressant adherence and persistence. At week 8 (or the exit interview if a subject leaves the study early), we will administer the Beck Depression Inventory and the Beck Anxiety Inventory. The primary outcome is treatment persistence, defined as the time to stop antidepressant use. Adherence, defined by the medication possession ratio (MPR), will be also be measured.
BACKGROUND: Endoplasmic reticulum (ER) stress causes neuroinflammation and neuronal apoptosis during ischemic stroke progression. This study has investigated the role of ALKBH5 in ER stress during ischemic stroke progression.
METHODS: In vivo and in vitro models of ischemic stroke were established by middle cerebral artery occlusion (MCAO) and OGD/R treatment, respectively. Cerebral infarct size was detected using triphenyltetrazolium chloride staining (TTC), and pathological changes were examined using histological staining. The levels of inflammatory factors were analyzed using Enzyme-linked immunosorbent assay. Cell counting kit-8 assay and flow cytometry were used to measure cell viability and apoptosis, respectively. The global m6A level was detected using the commercial kit, and STAT5 mRNA m6A level was determined using methylated RNA binding protein immunoprecipitation (Me-RIP). ALKBH5, YTHDF1, and STAT5 interactions were analyzed using RIP and RNA pull-down assays.
RESULTS: ALKBH5 was upregulated in MCAO animals and OGD/R cell models. ALKBH5 knockdown exacerbated ER stress, neuroinflammation, and neuronal apoptosis in brain tissues and neuronal cells. ALKBH5 inhibited STAT5 mRNA stability and expression in an m6A-YTHDF1-dependent manner. STAT5 promoted ER stress by activating the PERK/eIF2/CHOP signaling pathway. Furthermore, STAT5 knockdown reversed the effects of ALKBH5 knockdown on OGD/R-induced ER stress and neuroinflammation in HT22 cells.
CONCLUSION: ALKBH5 knockdown exacerbated ischemic stroke by increasing ER stress-dependent neuroinflammation and neuronal apoptosis via the STAT5/PERK/EIF2α/CHOP signaling pathway in an m6A-YTHDF1-dependent manner.
Metal complexes of new ligands of the formula ##STR1## are useful as agents for medical imaging, particularly MRI, for in vitro or in vivo diagnostic or as radiopharmaceuticals. In these compounds, X--R 1  --Y is a coordinating group able to form a highly stable complex with metal ions. Suitable units are for example derivatives of ortho-phenanthroline or of an hydroxamic acid. R 2  and R 3  are reactive functions such as amines or carboxylic groups. R 4  and R 5  are ligands, for instance diethylenetriaminepentaacetic acid 1,4,7,10-tetraacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,8,11-tetraazacyclotetradecane-N, N', N", N'"-tetraacetic acid (TETA), of a different type than the X--R 1  --Y units and able to strongly encapsulate metal ions with which the X--R 1  --Y moieties form less stable chelates. Stable high molecular weight multimetallic entities are spontaneously formed by these ligands that spontaneously associate around metal ions through the X--R 1  --Y units. Higher relaxivities thus are achieved. Mixed-complexes containing two different radionuclides are also obtained thus allowing imaging and therapy with one single chelate.
Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
The invention discloses a method for preparing a medicinal extract containing intermediate peashrub seeds. The method comprises the following steps: performing extraction enrichment, performing reduced pressure separation, dispersing and mixing uniformly; separating and encapsulating, homogenizing and filtering, and collecting to obtain sterile lipidosome of the medicinal extract containing intermediate peashrub seeds. According to the method disclosed by the invention, the oily medicinal extract is extracted and enriched from the intermediate peashrub seeds in a supercritical carbon dioxide environment, and the extract is mixed and encapsulated into drug-containing lipidosome nanoparticles by virtue of a film material. Compared with a traditional medical processing method for rendering the intermediate peashrub seeds or charking co-existence ground powder, the method disclosed by the invention has the advantages that the parameters in the operating process are controllable, the temperature is low, the active ingredients of plants can be well prevented from being damaged, and solvent residue is avoided. Moreover, the drug-containing lipidosome nanoparticles prepared by the invention have the characteristics of targeted drug delivery and long-term release, and because the cell-like structure has cell biocompatibility, drug release can be performed by virtue of a cell membrane. Therefore, the therapeutic index can be improved, and the method is suitable for treatment of skin diseases such as dermatitis, psoriasis, yellow-water sore and skin itch.
This study will employ a randomized, parallel-group design to determine the best strategy for mobile testing-and-treatment of rural opioid users for HCV. This Type 1 hybrid effectiveness-implementation study will examine the effectiveness of a model of mobile telemedicine service delivery integrated into rural harm reduction programming. The model aims to reach rural opioid injectors who are living with HCV and to fill service gaps identified in previous work around access to syringe services and HCV testing and treatment. Working closely with local harm reduction agencies, this study will employ a mobile van to expand antibody and viral load testing for HCV, distribute syringes in rural communities with poor access to brick-and-mortar syringe service providers, and provide HCV telemedicine treatment. The study will also replicate prior validation of the accuracy of dried blood spot (DBS) testing for HCV viral load as a potential strategy to address limited access to effective phlebotomy. All consenting volunteers with HCV antibody present will receive HCV viral load and liver elastography results, and, if current HCV carriers, initial vaccination for HBV and/or HAV. Participants with current HCV will be randomized to one of two intervention arms for HCV work-up and care.
Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring Tβ4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin β-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth.
The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
1. Technical Result Development of system of feeding antigens for improvement of safety and efficiency of immunization against various microbial agents and malignant growth. 2. Essence The present invention provides an immunogenic liposome composition comprising vesicle-forming lipids and an antigenic construct comprising one or more antigenic determinants and a hydrophobic domain. 3. Field of Application Medicine.
As the kynurenine pathway's links to inflammation, the immune system, and neurological disorders became more apparent, it attracted more and more attention. It is the main pathway through which the liver breaks down Tryptophan and the initial step in the creation of nicotinamide adenine dinucleotide (NAD+) in mammals. Immune system activation and the buildup of potentially neurotoxic substances can result from the dysregulation or overactivation of this pathway. Therefore, it is not shocking that kynurenines have been linked to neurological conditions (Depression, Parkinson's, Alzheimer's, Huntington's Disease, Schizophrenia, and cognitive deficits) in relation to inflammation. Nevertheless, preclinical research has demonstrated that kynurenines are essential components of the behavioral analogs of depression and schizophrenia-like cognitive deficits in addition to mediators associated with neurological pathologies due to their neuromodulatory qualities. Neurodegenerative diseases have been extensively associated with neuroactive metabolites of the kynurenine pathway (KP) of tryptophan breakdown. In addition to being a necessary amino acid for protein synthesis, Tryptophan is also transformed into the important neurotransmitters tryptamine and serotonin in higher eukaryotes. In this article, a summary of the KP, its function in neurodegeneration, and the approaches being used currently to target the route therapeutically are discussed.
PURPOSE:To obtain a hair restoration and growth stimulant containing a compound having a cinnamoyl type chemical structure as an active ingredient. CONSTITUTION:This hair restoration and growth stimulant is obtained by using a compound expressed by the formula (R1 is H, OH, a 1-3C alkyloxy, an aryl, etc.; R2 and R5 each is H, OH or a halogen; R3 is H, OH, an acyloxy, etc.; R4 is H, OH, a 1-5C alkyloxy, etc.), e.g. p-beta-D-glucopyranosyloxycinnamic acid as an active ingredient in an intact parent chemical or diluting the active ingredient in a suitable base for use. The hair restoration and growth stimulant can be prepared as a hair tonic, a hair cream, a hair lotion, a hair shampoo, a composition for ointments or plasters, etc., by suitably blending an additive such as a carrier, an emulsifier, a suspending agent or a flavoring agent usually used in the cosmetic or medicinal field. The amount of the compound, expressed by the formula and contained in the external preparations is 0.005-1%.